Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Lung and Upper Aerodigestive Cancer
National Cancer Institute (NCI)
Active, not recruiting ID
For more information, see NCT02581137
This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub off and can be associated with a higher risk of cancer. Metformin hydrochloride may help prevent oral cancer from forming in patients with an oral premalignant lesion.
Laboratory Biomarker Analysis, Metformin Hydrochloride
Erythroplakia, Hyperplasia, Oral Cavity Carcinoma, Oral Leukoplakia
Scott M Lippman

See list of participating sites